Continuous wound infusion of ropivacaine for the control of pain after thoracolumbar spinal surgery: a randomized clinical trial

Pain is the most commonly reported symptom in primary care after spinal surgery, while musculoskeletal pain accounts for half of all reported pain complaints [1]. The benefits of well-controlled postoperative pain include reduced postoperative cardiopulmonary complications, hospital mortality and length of hospital stay [2]. Modern pain control after major surgery involves a number of different analgesic modalities. Peripheral pain control by incisional local anesthesia is a new method in the treatment of postoperative pain especially after various surgical procedures. Wound infusion with local anesthetics can continuously infiltrate the peripheral nerve endings, and attenuates pain by directly blocking the neuronal membrane sodium channels. A single bolus of local anesthetics in the surgical site can provide a narcotic-limiting pain relief for 4–8 h after operation [3]. The time-limited effect of single bolus administration can be further improved through continuous surgical wound infusion techniques using multi-orifice-type catheters, positioned by the surgeon at the end of the procedure. A systematic review [4] of randomized controlled trials confirmed the benefits and safety of this technique when applied following several severely painful procedures, such as cardiac, thoracic and major gynecologic surgery. This technique remains effective in spinal surgery. Recently, Rushdi et al. [5] reported that the wound was infused with a solution of ropivacaine 0.4 %, suggesting the potential for the use of this method in major spinal surgery. The current study aimed to test the analgesic efficacy of wound infiltration with 1 % ropivacaine followed by an infusion of 0.33 % following thoracolumbar spinal surgery. Besides, we also evaluated and recorded the long-term effects of incisional local anesthesia on incidence of postoperative chronic pain and infection, compared with postoperative intravenous continuous constant-dose analgesia (ICCA).

After obtaining approval from the Local Research Ethics Committee, and written informed consent, our study included 71 ASA I-II patients, aged 18–75 years, scheduled for elective thoracolumbar spinal surgery since 2013 May to 2014 February. All 71 patients were randomly assigned to either the local (L) group (n = 35) or the intravenous (V) group (n = 36) using a computer-generated random number table. Exclusion criteria included: a history of cardiopulmonary disease, coagulation and merging with multiple injuries. One anesthesiologist was designated to provide postoperative management.

In the L group, we used continuous wound infusion with ropivacaine as primary analgesia. This group received an initial wound infiltration with 6 ml 1 % ropivacaine (100 mg; AstraZeneca AB, Sweden) and followed by continuous infusion with 0.33 % ropivacaine via a double lumen catheter system at a rate of 5 ml/h (Disposable Postoperative Local Analgesia System, Beijing Heng Yuan Tongji Medical Technology Corporation, China) for 48 h. Patient in L group did not receive postoperative intravenous continuous constant-dose analgesia (ICCA) for pain control. The V group (n = 36) relied on ICCA for postoperative pain control involved flurbiprofen axetil 150 mg, pentazocine 240 mg and palonosetron 0.5 mg in 100 ml normal saline, at a rate of 2 ml/h [5]. All patients expanded on the use of the supplementary analgesic (flurbiprofen 50 mg intravenous injection) if necessary (VAS ≥4).

Patients were premedicated with phenobarbital 100 mg and atropine 0.5 mg, 30 min before the induction of anesthesia. After baseline measurements of heart rate, noninvasive blood pressure, respiratory rate and oxygen saturation, each patient was preoxygenated for 3 min before induction. All patients received the target-controlled infusion with propofol 2–3 μg/ml using the Marsh pharmacokinetic model and remifentanil at 3–4 ng/ml using the Minto pharmacokinetic model for induction. Following the induction of anesthesia, cisatracurium 0.15 mg/kg was given as an intravenous injection. After tracheal intubation, mechanical ventilation was initiated with 100 % oxygen and adjusted to maintain the endtidal carbon dioxide tension between 35 and 45 mmHg. Intermittent bolus injection of cisatracurium was used to maintain full muscle relaxation. At the end of surgery, residual neuromuscular block was reversed, if needed, with a mixture of atropine and neostigmine. Patients were given pentazocine 60 mg when surgery was completed prior to extubation.

Overall, 94 patients were included in the study, and 23 patients were excluded after allocation (Fig. 1). All enrolled patients successfully completed the study and were included in the main analysis. Demographic data and surgical characteristics were not significantly different between the two groups (Table 1). No statistically significant differences were observed between the two groups with regard to operating time (L vs V, 251.91 ± 82.58 vs 246.39 ± 84.72 min; P = 0.95).

Postoperative VAS scores at rest were not significantly different between two groups (Fig. 2). During the postoperative 2 days, rescue analgesic medications were required 14 times in the L group and 15 times in the control group. All wound catheters were removed at 48 h postoperatively without any complications, but microbiologic culture of catheter tip from one patient detected Serratia marcescens.

Several secondary outcomes, except for the incidence of postoperative nausea or vomiting (P = 0.025), did not show any significant difference between groups (Fig. 3; Table 2). Six patients in the V group experienced mild postoperative nausea or vomiting and this did not require discontinuation of the pump. No patients in the L group reported postoperative nausea or vomiting, or obvious CNS toxic signs of ropivacaine. No major adverse event occurred in any patient. Pruritus, dizziness and wound drainage in each group, and CNS symptoms of ropivacaine intoxication in L group were not found.

The length of hospital stay and comprehensive evaluation were not significantly different between the two groups (Table 3). All patients received the same pattern of analgesic treatment at hospital discharge and compliance rate. At 3 months after the surgery, 3 patients (8.6 %) in L group and 14 patients (38.9 %) in V group reported residual wound pain (P < 0.05). One patient in L group, whose microbiologic culture detected S. marcescens, returned to hospital for further treatment.

Our research revealed that pain scores at rest during the 48 h postoperative period were not significantly different between the continuous ropivacaine wound infusion group and the ICCA group, suggesting that the two methods could achieve the same analgesic effect. More importantly, compared with the ICCA group, a positive effect on lightening chronic pain 3 months later and reducing the incidence of postoperative nausea and vomiting was existing.

In the research, we chose ropivacaine because of its lower systemic toxicity and its shorter elimination half-life, reducing the risk of plasma accumulation during prolonged infusion [6]. We used in this experiment 6 ml 1 % ropivacaine and followed by continuous infusion with 0.33 % ropivacaine via a double lumen catheter system at a rate of 5 ml/h for 48 h. This does/volume chosen was base on the reference [6].

The optimal method of providing analgesia with continuous wound infusion with local anesthetic in spinal surgery is still not conclusive. Variables such as the surgical plane in which the catheter is placed, the length and type of the catheter, the dose and duration of infusion still remain undetermined. Bianconi et al. [7] used continuous wound infusion with catheters placed between muscle fascia and subcutaneous tissue after spinal surgery. And they reported significant analgesic efficacy both in reducing pain scores and opioid use. However, studies have shown that subcutaneous infiltrations may not improve postoperative pain scores, although they do have an impact on opioid consumption [8, 9]. When compared with subfascial injection, the deeper infiltration results in better efficacy [10]. Therefore, we chose the above and below the muscle fascia catheter location. In this study, none of our catheter implantations affected wound drainage.

Although some authors [11, 12] have concerns that wound infiltration with local anesthetic may interfere with wound closure and normal wound healing. Until now, there is no definitive data on mature wound strength after wound infusion analgesia. Hopf et al. [13] highlighted that postoperative pain could affect the inflammatory response and increase catecholamine release, leading to wound perfusion and oxygenation decline. Conversely, it is possible that partial blockade of the inflammatory response in the first phase of wound closure by wound infiltration with local anesthetics through providing good pain control may be beneficial and result in less fibroblast hyperplasia. As Watanabe et al. [14] suggests, fluid infused into a wound with saline may have an effect in decreasing the pain response because it can dilute and wash out pain substances such as histamine and vasoactive polypeptides.

Questions remain regarding the potential risk of wound infection when providing analgesia with continuous wound infusion with local anesthetic. Our microbiologic culture results showed S. marcescens in one patient in the L group. The reason was unknown. But since non-thorough aseptic procedure during routine surgeries also occasionally causes Serratia, we believe this case is not directly related to the catheter implantation. Moreover, the wound infection rates did not differ between the two groups (P > 0.05), suggesting that the catheter does not increase the risk of wound infection in local anesthetic infusion patients. In a meta-analysis by Liu et al. [4], the overall wound infection rate was similar between catheter with local anesthetic (0.7 %) and catheter with placebo or the no-catheter control group (1.2 %). It was also reported that the incidence of catheter or pump failure was 1.1 %. Although it has been reported that the local anesthetic ropivacaine displays antimicrobial activity [15], a study of continuous ropivacaine infusion in the median sternotomy incision following cardiac surgery showed high infection rates (9 %, n = 44) and this rate of infection was not statistically different in the saline group (0 %, n = 41) (P > 0.05) [16]. However, a larger sample size must be evaluated before a definitive conclusion can be drawn about the safety of this technique.

Chronic pain is known to severely affect quality of life and has significant economic consequences [6]. On stripping of muscle attachment points and injury of soft tissue in our research, there was an 8.6 and 38.9 % incidence of dull pain within the local operative area independent of the primary pain in L group and V group, respectively (P < 0.05). We suspect that the local anesthetic acts directly on the surgical site, cutting off the source of harmful stimulation, this might cause the difference between two groups. An recent experimental study on rat, mouse, monkey and humans has suggested that a long noncoding RNA contributes to neuropathic pain following nerve injury [17]. And Attal et al. [18] in a double-blind controlled crossover study with a 2-week washout period evaluated the effect of lidocaine. A decrease in spontaneous pain, mechanical dynamic allodynia, static mechanical allodynia, and hyperalgesia was demonstrated. It was thought that washout of the injured site was dedicated to mitigating to peripheral neuropathic pain. In recent pharmaceutical developments, flurbiprofen has been introduced as a parental drug carrier acting as a sustained-release formulation and targeting injured tissue [6]. However, flurbiprofen was mainly persisted retention in the blood circulation and passively targeted to the site of injury with a highly permeable capillary endothelium. The transmission of pain stimuli to the spinal cord cannot be inhibited completely by flurbiprofen, which leads to long noncoding RNA changes, and less effective inhibition of the incidence of chronic pain than the local anesthetics.

In conclusion, the efficacy of continuous surgical wound infusion with local anesthetics was tested using multiholed catheters placed above and below the muscle fascia after thoracolumbar spinal surgery. Our study showed that continuous wound analgesia infusion pump could achieve the same analgesic effect as ICCA during hospitalization after spine surgery, while avoiding intravenous analgesic drug-induced adverse effects such as postoperative nausea and vomiting. More importantly, continuous surgical wound infusion with local anesthetics is superior to ICCA in reducing the incidence of chronic pain. Since the number of patients in our study is small, the risk of bias cannot be ignored when we make such conclusion. However, this therapy could be an important component of multimodal approaches for postoperative pain management.